#USA #San Diego #Tumoroids #Discovery Life Sciences #OncoPro

Discovery Life Sciences Set to Revolutionize Cancer Research with New Tumoroids

Discovery Life Sciences, a renowned global leader in biospecimen solutions and specialized laboratory services, is poised to launch its groundbreaking Tumoroid Cell Lines at the upcoming Precision Med Tri-Con 2025. This significant event is scheduled to take place from March 11 to 13 in San Diego, California.

The Tumoroid Cell Lines, developed using the innovative OncoPro™ Medium from Thermo Fisher Scientific, present a transformative tool for oncology research. McLean Collins, the chief executive officer of Biospecimen Products and Services at Discovery, stated, "Our Tumoroid cell lines serve as a powerful predictive tool that can help eliminate significant barriers in cancer research, enabling scientists to identify life-changing therapies more swiftly."

The tumor-derived cell lines, grown as self-organizing three-dimensional multicellular structures, provide a more biologically relevant model compared to traditional two-dimensional cancer models. These structures are instrumental in drug development and diagnostics, potentially revolutionizing how scientists understand and approach cancer therapies.

Highlights of Tri-Con 2025

In addition to unveiling the Tumoroid Cell Lines, Discovery Life Sciences will participate in various scientific engagements at Tri-Con. Notable presentations include:

• - A luncheon presentation by Dr. Shawn Fahl, Vice President of Laboratory Operations, Cellular Services, and R&D, on the transition from biorepositories to accelerated development with spatial and transcriptomic analysis on March 11.
• - A panel discussion on technological trends in precision medicine, where Dr. Fahl will share insights on emerging innovations in the field on March 12.
• - A poster presentation titled "Cell-Free DNA and Beyond: A Comprehensive Assessment of Liquid Biopsy Workflows in a Global Clinical Biorepository."

Dr. Fahl emphasized, "This year at Precision Med Tri-Con, we are excited to present several compelling studies that highlight our commitment to advancing precision medicine by integrating advanced technologies and high-quality biological specimens into our workflows. We look forward to collaborating with the scientific community to explore new ways to shape the future of cancer research together."

Discovery Life Sciences has made strategic investments in advanced technologies, including AI-driven pathology and workflows for retrospective clinical biomarker testing. These investments enable clients to extract quantitative and actionable insights from biospecimens, significantly enhancing research outcomes.

For more information about the innovative Tumoroid Cell Lines and other offerings from Discovery Life Sciences, visit www.dls.com.

About Discovery Life Sciences

Discovery Life Sciences stands at the forefront of biospecimen and specialized laboratory services, empowering the discovery and development of therapies and diagnostics that enhance patient outcomes. With a comprehensive portfolio of biospecimens, cellular starting materials, and preclinical ADME-tox solutions, Discovery accelerates research with reliable and high-quality products and expertise. Through its extensive services in genomics, proteomics, cellular biology, and molecular pathology, Discovery provides critical data and insights essential for biomarker discovery and clinical trials, both retrospective and prospective.

With a vision to be the most trusted partner in the clinical research and development of biological sciences, Discovery Life Sciences is dedicated to advancing biological sciences and transforming lives. Visit www.dls.com for further details.